Screener
Vertex Pharmaceuticals VRTX Business Segments — Acquired in-process research and development expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of sales - royalty | 232.6 | 232.4 |
| Research expenses | 205.0 | 206.1 |
| Development expenses | 756.6 | 773.6 |
| Acquired in-process research and development expenses | 0.5 | 19.8 |
| Selling and other commercial expenses | 313.6 | 241.1 |
| General and administrative expenses | 180.1 | 155.3 |
| Intangible asset impairment charge | — | 379.0 |
| Interest income, net | (114.8) | (117.9) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses?
- Vertex Pharmaceuticals (VRTX) reported business segments — acquired in-process research and development expenses of $500K in Q1 2026.
- How has Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses changed year-over-year?
- Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses decreased by 97.5% year-over-year, from $19.8M to $500K.
- What is the long-term trend for Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses has grown at a 4.8% compound annual growth rate (CAGR), from $115.5M to $133M.
- What does business segments — acquired in-process research and development expenses mean?
- One-time costs related to the acquisition of research and development projects from other companies or through licensing agreements. These represent inorganic growth strategies to bolster the pipeline.
Ask your AI about Vertex Pharmaceuticals's business segments — acquired in-process research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude